Second-line axicabtagene ciloleucel in large B-cell lymphoma ineligible for transplantation: ALYCANTE final analysis - Takeaways - MDSpire
Coming Soon: Introducing MDSpire News. Learn more
Conexiant’s news site is now MDSpire News. Learn more

Final Analysis of Second-Line Axicabtagene Ciloleucel for Large B-Cell Lymphoma Patients Not Eligible for Transplantation: ALYCANTE Study Results

  • By

  • Roch Houot

  • Jean Lemoine

  • Alexis Claudel

  • Emmanuel Bachy

  • Guillaume Cartron

  • François-Xavier Gros

  • Franck Morschhauser

  • Lucie Oberic

  • Thomas Gastinne

  • Pierre Feugier

  • Rémy Duléry

  • Catherine Thieblemont

  • Magalie Joris

  • Fabrice Jardin

  • Sylvain Choquet

  • Olivier Casasnovas

  • Gabriel Brisou

  • Morgane Cheminant

  • Jacques-Olivier Bay

  • Jules Coville

  • Francisco Llamas-Gutierrez

  • Karin Tarte

  • Cédric Portugues

  • Emmanuel Itti

  • Xavier Palard-Novello

  • Paul Blanc-Durand

  • Yassine Al Tabaa

  • Clément Bailly

  • Camille Laurent

  • François Lemonnier

  • September 22, 2026

Share

  • 1

    Axicabtagene ciloleucel (axi-cel) is a standard second-line treatment for patients with refractory/relapsed large B-cell lymphoma.

  • 2

    The ALYCANTE trial showed a 3-month complete metabolic response rate of 71.0% in patients ineligible for transplantation.

  • 3

    At a median follow-up of 37.4 months, the median progression-free survival was 18.0 months, while overall survival had not been reached.

  • 4

    Grade ≥3 adverse events occurred in 96.8% of patients, with neutropenia being the most frequent adverse event reported.

  • 5

    The final analysis confirmed durable responses to axi-cel, with no new safety signals identified across age and comorbidity subgroups.

Original Source(s)

Second-line axicabtagene ciloleucel in large B-cell lymphoma ineligible for transplantation: ALYCANTE final analysis

  • by Roch Houot, Jean Lemoine, Alexis Claudel, Emmanuel Bachy, Guillaume Cartron, François-Xavier Gros, Franck Morschhauser, Lucie Oberic, Thomas Gastinne, Pierre Feugier, Rémy Duléry, Catherine Thieblemont, Magalie Joris, Fabrice Jardin, Sylvain Choquet, Olivier Casasnovas, Gabriel Brisou, Morgane Cheminant, Jacques-Olivier Bay, Jules Coville, Francisco Llamas-Gutierrez, Karin Tarte, Cédric Portugues, Emmanuel Itti, Xavier Palard-Novello, Paul Blanc-Durand, Yassine Al Tabaa, Clément Bailly, Camille Laurent, François Lemonnier

  • September 22, 2026

Related Content

Posterior fossa ependymoma: a comprehensive review of molecular classification, management guidelines, and clinical outcomes (Part I of ependymomas across compartments)

Cancer Treatment During Pregnancy and Maternal and Infant Outcomes: A Descriptive Cohort Study Using a Japanese Claims Database

A New Era for Pancreatic Cancer: How Baptist Health Research Helped Get Us Here

Pancreatic adenocarcinoma, the most common form of pancreatic cancer, accounts for roughly 90 to 95 percent of cases. It's notoriously difficult to catch early, because symptoms often don't appear until the disease has already spread

  • by

  • September 24, 2026

  • 11 min